Medbright AI Investments Inc MBAIF

MedMatrix Moving to Full Commercialization w/ Completed Beta

[MarketMakerss]

Today, MedBright AI (MBAI.c MBAIF) announced the completion of its beta testing for MedMatrix and that it is now moving the platform to full commercialization with an AI product suite.

 

As detailed in this short introduction video, MedMatrix is an AI-powered data analytics platform and engine that analyzes crucial aspects of healthcare facilities and works alongside healthcare professionals to drastically improve healthcare operations and enhance clinic revenue by 10% at no additional cost to the clinic: https://youtu.be/f3bcx2T_GzQ?si=9CXluAYD43PEDMM9

 

Following the completion of beta testing with its initial clients, MBAI has chosen a five-feature product suite to sell into the global outpatient facility market which have been identified as high-value tools:

1. AI Reporter: Data reporting from AI analytics platform, a complete dashboard of a clinic's operations and the MedMatrix forecaster
2. AI Market Expander: Analyzes providers' current clinic locations and allows them to assess the potential demand in the market based on patient demographics, competition, facility costs, and other key factors.
3. AI Resource Matcher: Virtual assistant to front office administration analyzing patient needs at the time of scheduling and matching them to the appropriate resources within the clinic
4. AI Claim Optimizer: Analyzes a clinic's claim data to look at key performance indicators for revenue cycle management
5. AI Revenue Enhancer: Finds opportunities for revenue growth based on a clinic's existing patient base and revenue models

 

MBAI CEO, Trevor Vieweg, commented,

“It is gratifying to complete the beta phase as we move towards the revenue generation phase of the MedMatrix product. We have identified these five feature sets based on their ability to generate revenue for our outpatient clinic clients, and we look forward to highlighting the use cases for these tools with our initial customers in the coming months, as well as expanding our customer base as we transition to full commercialization.”

 

This is a major milestone for MBAI that comes on the heels of its previously expanded offerings for MedMatrix, as seen with Rejuvenation, a prominent dermatology group and leader in advanced dermatological care, expanding its already established use of MedMatrix to include marketing for cosmetic treatments and clinical trial recruitment and data analysis.

 

This is a significant demonstration of both the substantial scalability and the vast addressable market that is open to MedMatrix and, as MBAI continues to execute on this path, it could mean quick multiples from successfully solving even a small percentage of the addressable market.

 

Despite having an mcap of only $18M, MBAI's Beta test saw MedMatrix's adoption in 14 clinics, including a Yale University-Affiliated Clinic, and is strongly positioned to fix the $200 billion healthcare problem of congested waiting rooms.

 

Full News Release: https://www.globenewswire.com/news-release/2024/02/27/2835946/0/en/MedMatrix-Product-Moves-from-Beta-to-Full-Commercialization-Announces-AI-Product-Suite.html

 

Posted on Behalf of MedBright AI Investments Inc.